Dihydrodigoxin

CAS: 5297-10-9

Ref. 3D-FAA29710

Produktinformation

• Name: Dihydrodigoxin
• Synonyme: (3β,5β,12β)-3-[(O-2,6-Dideoxy-β-<span class="text-smallcaps">D</smallcap>-ribo-hexopyranosyl-(1→4)-O-2,6-dideoxy-β-<smallcap>D</smallcap>-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-<smallcap>D</span>-ribo-hexopyranosyl)oxy]-12,14-dihydroxycardanolide, 20,22-Dihydrodigoxin, 3-{[2,6-Dideoxyhexopyranosyl-(1->4)-2,6-Dideoxyhexopyranosyl-(1->4)-2,6-Dideoxyhexopyranosyl]Oxy}-12,14-Dihydroxycardanolide, 5β-Cardanolide, 3β-[(O-2,6-dideoxy-β-<span class="text-smallcaps">D</smallcap>-ribo-hexopyranosyl-(1→4)-O-2,6-β-<smallcap>D</smallcap>-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-<smallcap>D</span>-ribo-hexopyranosyl)oxy]-12β,14-dihydroxy-, Brn 1339019, Cardanolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3-beta,5-beta,12-beta)-, Cardanolide, 3-((O-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1.4)-O-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1.4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-, Cardanolide, 3-[(O-2,6-dideoxy-β-<span class="text-smallcaps">D</smallcap>-ribo-hexopyranosyl-(1→4)-O-2,6-dideoxy-β-<smallcap>D</smallcap>-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-<smallcap>D</span>-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-, (3β,5β,12β)-, Digoxin, 20,22-dihydro-, Digoxin, dihydro-, Digoxin, dihydro- (6CI)

Beschreibung

Dihydrodigoxin is a cardiac glycoside that has been used in the treatment of congestive heart failure. It is usually administered orally and can be detected by fluorescence detector because it contains a fluorescent derivative. Dihydrodigoxin has been shown to decrease renal excretion of digoxin, which may lead to drug interactions. This drug also decreases the activity of several enzymes, including dehydroascorbic acid reductase (DHAR). DHAR catalyzes the conversion of dehydroascorbic acid to ascorbic acid, which is necessary for collagen synthesis. Dihydrodigoxin also causes preeclampsia in pregnant women and decreases blood flow to the uterus.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 783 g/mol
• Formel: C₄₁H₆₆O₁₄
• Reinheit: Min. 95%
• Farbe/Form: Powder